Trial Profile
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Pharmacodynamics; Registrational
- Sponsors Allergan
- 02 Apr 2022 This trial has been completed in France (End Date: 5 Dec 2012) according to European Clinical Trials Database record.
- 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Feb 2011 New source identified and integrated (Clinical Trials Registry - India, CTRI2009-091-000360).